Scotiabank Initiates Disc Medicine at Sector Outperform
Disc Medicine Announces Presentation of New Data From Phase 1b Trial of DISC-0974 in Patients With Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Express News | Disc Medicine Announces Presentation of New Data From Phase 1B Trial of Disc-0974 in Patients With Chronic Kidney Disease (Ckd) and Anemia at 2024 American Society of Nephrology (Asn) Kidney Week
Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald
Express News | Disc Medicine Expands Leadership Team With Appointment of Industry Veteran Steve Caffé, Md as Chief Regulatory Officer
Press Release: Disc Medicine Expands Leadership Team With Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Disc Medicine's Chief Medical Officer Sells Shares Worth Over $71k
HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright analyst Douglas Tsao maintains $Disc Medicine(IRON.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 45.8%
Buy Rating Affirmed for Disc Medicine on Promising Drug Pipeline and Strategic Developments
Disc Medicine to Participate in Upcoming Investor Conferences
Wells Fargo Initiates Disc Medicine at Overweight With $75 Price Target
Wells Fargo Initiates Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $75
Wells Fargo analyst Tiago Fauth initiates coverage on $Disc Medicine(IRON.US)$ with a buy rating, and sets the target price at $75.According to TipRanks data, the analyst has a success rate of 45.2%
Optimistic Outlook on Disc Medicine's Pipeline and Investment Potential
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Companies Like Disc Medicine (NASDAQ:IRON) Are In A Position To Invest In Growth
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
Wedbush Reiterates Outperform on Disc Medicine, Maintains $57 Price Target
Disc Medicine (IRON) Gets a Hold From Morgan Stanley
Disc Medicine (IRON) Receives a New Rating From Wedbush